Search results for "Lymphocyte"

showing 10 items of 2280 documents

Generation of tumor-reactive CTL against the tumor-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoiet…

2000

Abstract Ag-specific CD8+ CTL are crucial for effective tumor rejection. Attempts to treat human malignancies by adoptive transfer of tumor-reactive CTL have been limited due to the difficulty of generating and expanding autologous CTL with defined Ag specificity. The current study examined whether human CTL can be generated against the tumor-associated Ag HER2 using autologous dendritic cells (DC) that had been genetically engineered to express HER2. DC progenitors were expanded by culturing CD34+ hemopoietic progenitor cells in the presence of the designer cytokine HyperIL-6. Proliferating precursor cells were infected by a retroviral vector encoding the HER2 Ag and further differentiated…

Cytotoxicity ImmunologicAdoptive cell transferReceptor ErbB-2T cellRecombinant Fusion ProteinsImmunologyAntigen-Presenting CellsImmunoglobulinschemical and pharmacologic phenomenaAntigens CD34BiologyMajor histocompatibility complexLymphocyte ActivationViral vectorCell LineAntigens CDTransduction GeneticMHC class IHLA-A2 AntigenmedicineTumor Cells CulturedImmunology and AllergyHumansProgenitor cellskin and connective tissue diseasesAntigen PresentationMembrane GlycoproteinsInterleukin-6Cell DifferentiationDendritic CellsReceptors InterleukinHematopoietic Stem CellsMolecular biologyReceptors Interleukin-6Peptide FragmentsCell biologyClone CellsCTL*medicine.anatomical_structureRetroviridaebiology.proteinCD8Cell DivisionT-Lymphocytes CytotoxicJournal of immunology (Baltimore, Md. : 1950)
researchProduct

Cellular cytotoxicity against autologous hepatocytes in alcoholic liver disease.

2008

We tested lymphocyte cytotoxicity against autologous hepatocytes in patients with alcoholic liver disease (ALD). The following cytotoxicity values were found (mean +/- SEM): alcohol-induced steatosis with or without fibrosis 16.5 +/- 2% (n = 29), alcoholic cirrhosis 28 +/- 4% (n = 13), controls with normal liver histology or minimal changes 6 +/- 2% (n = 11). The differences were statistically significant (both forms of ALD versus controls p less than 0.005). T-cell as well as non-T-cell-enriched lymphocyte fractions showed increased cytotoxicity in ALD. We did not observe a correlation between cellular cytotoxicity and the degree of biochemical or histological alterations within the groups…

Cytotoxicity ImmunologicAlcoholic liver diseasemedicine.medical_specialtyPathologyCirrhosisHepatologyLymphocyteHepatobiliary diseaseBiologyMiddle Agedmedicine.diseasemedicine.anatomical_structureEndocrinologyLiverFibrosisLiver Cirrhosis AlcoholicHepatocyteInternal medicinemedicineHumansSteatosisCytotoxicityFatty Liver AlcoholicT-Lymphocytes CytotoxicLiver
researchProduct

Consequences of antigen self-presentation by tumor-specific cytotoxic T cells.

2000

Abstract CDS-positive cytotoxic T cells (CTL) recognize antigenic peptides in combination with major histocompatibility complex (MHC) class I molecules on the surface of syngeneic antigen presenting cells (APC). In the present paper we show that cells from tumor antigen-specific CTL clones present their cognate antigenic peptide to other CTL from the same clone. Inter-CTL peptide presentation resulted in activation of the cells of one CTL clone to MHC-unrestricted lysis of bystander cells. In contrast to the behaviour of this clone, another CTL clone did not lyse bystander cells after incubation with the cognate peptide, but was activated to self-destruction. The human herpes virus Epstein-…

Cytotoxicity ImmunologicAntigen PresentationbiologyT cellImmunologyAntigen presentationchemical and pharmacologic phenomenaHematologyMHC restrictionMajor histocompatibility complexMolecular biologyCTL*medicine.anatomical_structureAntigenHLA-A2 Antigenbiology.proteinmedicineTumor Cells CulturedImmunology and AllergyCytotoxic T cellHumansAntigen-presenting cellCell Line TransformedT-Lymphocytes CytotoxicImmunobiology
researchProduct

Gemcitabine sensitizes lung cancer cells to Fas/FasL system-mediated killing

2014

Gemcitabine is a chemotherapy agent commonly used in the treatment of non-small cell lung cancer (NSCLC) that has been demonstrated to induce apoptosis in NSCLC cells by increasing functionally active Fas expression. The aim of this study was to evaluate the Fas/Fas ligand (FasL) system involvement in gemcitabine-induced lung cancer cell killing. NSCLC H292 cells were cultured in the presence or absence of gemcitabine. FasL mRNA and protein were evaluated by real-time PCR, and by Western blot and flow cytometry, respectively. Apoptosis of FasL-expressing cells was evaluated by flow cytometry, and caspase-8 and caspase-3 activation by Western blot and a colorimetric assay. Cytotoxicity of ly…

Cytotoxicity ImmunologicAntimetabolites AntineoplasticFas Ligand ProteinLung NeoplasmsImmunologychemical and pharmacologic phenomenaApoptosisSettore MED/10 - Malattie Dell'Apparato RespiratorioDeoxycytidineFas ligandFlow cytometryCarcinoma Non-Small-Cell LungCell Line TumormedicineImmunology and AllergyCytotoxic T cellHumansfas ReceptorLung cancerAutocrine signallingKiller Cells Lymphokine-ActivatedCaspase 8Lymphokine-activated killer cellmedicine.diagnostic_testChemistryCaspase 3Original Articlesmedicine.diseaseMolecular biologyGemcitabineGemcitabineApoptosisapoptosis cytotoxic lymphocytes non-small cell lung cancermedicine.drug
researchProduct

T cells engineered to express a T-cell receptor specific for glypican-3 to recognize and kill hepatoma cells in vitro and in mice

2015

Background & Aims Cancer therapies are being developed based on our ability to direct T cells against tumor antigens. Glypican-3 (GPC3) is expressed by 75% of all hepatocellular carcinomas (HCC), but not in healthy liver tissue or other organs. We aimed to generate T cells with GPC3-specific receptors that recognize HCC and used them to eliminate GPC3-expressing xenograft tumors grown from human HCC cells in mice. Methods We used mass spectrometry to obtain a comprehensive peptidome from GPC3-expressing hepatoma cells after immune-affinity purification of human leukocyte antigen (HLA)-A2 and bioinformatics to identify immunodominant peptides. To circumvent GPC3 tolerance resulting from feta…

Cytotoxicity ImmunologicCancer Immunotherapy ; Immune Response ; Liver Cancer ; Tumor-associated AntigensCarcinoma HepatocellularTime FactorsCell SurvivalMice SCIDCD8-Positive T-LymphocytesBiologyLymphocyte ActivationTransfectionImmunotherapy AdoptiveInterferon-gammaInterleukin 21GlypicansHLA-A2 AntigenAnimalsHumansCytotoxic T cellIL-2 receptorAntigen-presenting cellInterleukin 3HepatologyImmunodominant EpitopesZAP70Liver NeoplasmsGastroenterologyDendritic CellsHep G2 CellsNatural killer T cellXenograft Model Antitumor AssaysMolecular biologyCoculture TechniquesGenes T-Cell ReceptorInterleukin 12FemaleGenetic Engineering
researchProduct

Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia

2021

BackgroundT-cell acute lymphoblastic leukemia (T-ALL) is an aggressive disease with a poor cure rate for relapsed/resistant patients. Due to the lack of T-cell restricted targetable antigens, effective immune-therapeutics are not presently available and the treatment of chemo-refractory T-ALL is still an unmet clinical need. To develop novel immune-therapy for T-ALL, we generated an afucosylated monoclonal antibody (mAb) (ahuUMG1) and two different bispecific T-cell engagers (BTCEs) against UMG1, a unique CD43-epitope highly and selectively expressed by T-ALL cells from pediatric and adult patients.MethodsUMG1 expression was assessed by immunohistochemistry (IHC) on a wide panel of normal t…

Cytotoxicity ImmunologicCancer Research2434T-LymphocytesMice SCIDafucosylated monoclonal antibodyLymphocyte ActivationPrecursor T-Cell Lymphoblastic Leukemia-LymphomaEpitopesJurkat CellsAntineoplastic Agents ImmunologicalAntibody SpecificityMice Inbred NODantigensAntibodies BispecificTumor MicroenvironmentImmunology and Allergyantibodieshematologic neoplasms1506RC254-282Antibody-dependent cell-mediated cytotoxicityLeukosialinbispecific T-cell engagersmedicine.diagnostic_testbiologyhematological malignancieNeoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.anatomical_structureantibodieOncologytranslational medical researchMolecular MedicineImmunohistochemistryFemaleimmunotherapyAntibodyT-ALLT-cell engagersT-cell acute lymphoblastic leukemiamedicine.drug_classT cellImmunologySettore MED/08 - Anatomia PatologicaMonoclonal antibodyAntibodies Monoclonal HumanizedFlow cytometryT Acute Lymphoblastic LeukemiaantigenAntigenPhagocytosismedicineAnimalsHumanshematological malignanciesCell ProliferationPharmacologyT-cell engagerbusiness.industryhematological malignancies; antibodies; antigens; hematologic neoplasms; immunotherapy; neoplasm; T-ALL; T-cell engagers; translational medical research; translational researchBasic Tumor ImmunologyXenograft Model Antitumor Assaystranslational researchCancer researchbiology.proteinneoplasmbusinesshematologic neoplasmneoplasm
researchProduct

HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-…

2000

The HER-2/neu oncoprotein, a 185 kDa membrane-associated tyrosine kinase with extensive homology to the epidermal growth factor receptor (EGF-R), is overexpressed in breast and ovarian carcinomas. Its overexpression is closely associated with poor prognosis in the course of disease. Here we demonstrate HER-2/neu overexpression in both established cell lines and biopsy material obtained from renal epithelial tumors. Immunohistochemical analysis of human kidney tumor lesions using 2 HER-2/neu-specific antibodies revealed HER-2/neu expression in more than 40% of primary epithelial renal tumors and more than 30% of primary renal cell carcinoma (RCC) specimens. A distinctive HER-2/neu expression…

Cytotoxicity ImmunologicCancer ResearchCellular immunityPathologymedicine.medical_specialtyReceptor ErbB-2BiologyEpitopeEpitopesAntigenRenal cell carcinomaAntigens NeoplasmHLA-A2 AntigenmedicineCytotoxic T cellHumansRNA MessengerRNA NeoplasmCarcinoma Renal CellNeoplasm StagingDendritic CellsGenes erbB-2medicine.diseaseKidney NeoplasmsPeptide FragmentsNeoplasm ProteinsCTL*OncologyCancer researchbiology.proteinImmunohistochemistryAntibodyT-Lymphocytes CytotoxicInternational journal of cancer
researchProduct

Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A

1999

Peptides derived from the melanoma-associated MART-1/Melan-A antigen are currently implemented in immunotherapy for inducing or augmenting T-cell responses directed against peptides expressed by autologous tumor cells in HLA-A2+ patients with melanoma. Here, we describe the specificity of the T-cell clone SK29-FFM1.1, which secretes GM-CSF in response to a panel of synthetic MART-1/Melan-A-derived peptides, including the naturally presented ILTVILGVL32–40, but exhibits cytotoxicity and IFN-γ secretion exclusively to the MART-1/Melan-A derived peptide AAGIGILTV27–35. In addition, cytotoxic T-lymphocyte (CTL) clone SK29-FFM1.1 recognizes 3 different naturally processed and presented peptides …

Cytotoxicity ImmunologicCancer ResearchCellular immunityReceptors Antigen T-Cell alpha-betaT-Lymphocytesmedicine.medical_treatmentBiologyTransfectionEpitopeInterferon-gammaMART-1 AntigenImmune systemAntigenAntigens NeoplasmHLA-A2 AntigenTumor Cells CulturedmedicineHumansProtein IsoformsCytotoxic T cellAmino Acid SequenceMelanomaneoplasmsintegumentary systemReverse Transcriptase Polymerase Chain ReactionImmunotherapyMolecular biologyRecombinant ProteinsClone CellsNeoplasm ProteinsCTL*OncologyImmunologyClone (B-cell biology)T-Lymphocytes CytotoxicInternational Journal of Cancer
researchProduct

Frequency analysis of tumor-reactive cytotoxic T lymphocytes in peripheral blood of a melanoma patient vaccinated with autologous tumor cells

1994

A limiting-dilution assay was developed and used to determine the frequency of autologous tumor-reactive cytotoxic T lymphocytes (CTL) in peripheral blood of a melanoma patient MZ2, who has been free of detectable disease since several years. In this patient, the frequencies of tumor-reactive CTL spontaneously varied only by a factor of 1.5. After vaccinations with autologous mutagenized and lethally irradiated tumor cells a two- to tenfold increase in frequencies of tumor-reactive CTL was found within the first 2 weeks. Thereafter, CTL frequencies returned to values measured prior to vaccinations. We conclude, that the limiting-dilution assay applied in this study can detect changes in the…

Cytotoxicity ImmunologicCancer ResearchCellular immunitymedicine.medical_treatmentImmunologyActive immunizationLeukocyte CountImmune systemTumor Cells CulturedmedicineHumansImmunology and AllergyCytotoxic T cellAmelanotic melanomaMelanomaCells Culturedbusiness.industryVaccinationReproducibility of ResultsImmunotherapyT lymphocytemedicine.diseaseCTL*OncologyImmunologyImmunotherapyLymphocyte Culture Test MixedbusinessT-Lymphocytes CytotoxicCancer Immunology Immunotherapy
researchProduct

FOXP3 Inhibitory Peptide P60 Increases Efficacy of Cytokine-induced Killer Cells Against Renal and Pancreatic Cancer Cells

2019

Background/aim Cytokine-induced killer (CIK) cells are ex vivo expanded major histocompatibility complex (MHC)-unrestricted cytotoxic cells with promising effects against a variety of cancer types. Regulatory T-cells (T-reg) have been shown to reduce the effectiveness of CIK cells against tumor cells. Peptide P60 has been shown to inhibit the immunosuppressive functions of T-regs. This study aimed at examining the effect of p60 on CIK cells efficacy against renal and pancreatic cancer cells. Materials and methods The effect of P60 on CIK cytotoxicity was examined using flow cytometry, WST-8-based cell viability assay and interferon γ (IFNγ) ELISA. Results P60 treatment resulted in a signifi…

Cytotoxicity ImmunologicCancer ResearchFOXP3Cell SurvivalImmunotherapy.KidneyMajor histocompatibility complexT-Lymphocytes RegulatoryInterferon-gamma03 medical and health sciencesCytokine-Induced Killer Cells0302 clinical medicineCytokine-induced killer (CIK) cellCell Line TumorPancreatic cancermedicineHumansCytotoxic T cellViability assayCytotoxicityPancreasCancerCytokine-induced killer cellbiologyChemistryFOXP3Forkhead Transcription FactorsGeneral Medicinemedicine.diseaseCoculture TechniquesKidney NeoplasmsPancreatic NeoplasmsOncologyCell culture030220 oncology & carcinogenesisAdoptive cell transferCancer researchbiology.proteinCytokinesPeptidesAnticancer Research
researchProduct